← Back to Screener
Instil Bio, Inc. Common Stock (TIL)
Price$8.39
Favorite Metrics
Price vs S&P 500 (26W)-62.57%
Price vs S&P 500 (4W)-5.63%
Market Capitalization$60.22M
All Metrics
Book Value / Share (Quarterly)$16.79
P/TBV (Annual)0.22x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-6.87
Price vs S&P 500 (YTD)-23.41%
EPS (TTM)$-10.78
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-10.78
EPS (Annual)$-11.37
ROI (Annual)-29.18%
Cash / Share (Quarterly)$11.23
ROA (Last FY)-28.08%
EBITD / Share (TTM)$-10.33
ROE (5Y Avg)-43.06%
Cash Flow / Share (Annual)$-6.87
P/B Ratio0.53x
P/B Ratio (Quarterly)0.66x
Net Income / Employee (Annual)$-5
Net Interest Coverage (TTM)-129.63x
ROA (TTM)-32.31%
EPS Incl Extra (Annual)$-11.37
Current Ratio (Annual)39.53x
Quick Ratio (Quarterly)39.11x
3-Month Avg Trading Volume0.10M
52-Week Price Return-41.96%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.79
P/S Ratio (Annual)430.17x
Asset Turnover (Annual)0.00x
52-Week High$42.79
EPS Excl Extra (Annual)$-11.37
CapEx CAGR (5Y)-27.76%
26-Week Price Return-53.82%
Quick Ratio (Annual)39.11x
13-Week Price Return23.50%
Total Debt / Equity (Annual)0.74x
Current Ratio (Quarterly)39.53x
Enterprise Value$138.392
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-26850.00%
Cash / Share (Annual)$11.23
3-Month Return Std Dev47.26%
Net Income / Employee (TTM)$-5
ROE (Last FY)-43.67%
Net Interest Coverage (Annual)-20.08x
EPS Basic Excl Extra (Annual)$-11.37
Total Debt / Equity (Quarterly)0.74x
EPS Incl Extra (TTM)$-10.78
ROI (TTM)-33.63%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.79
Price vs S&P 500 (52W)-77.06%
Year-to-Date Return-19.27%
5-Day Price Return6.28%
EPS Normalized (Annual)$-11.37
ROA (5Y Avg)-31.97%
Net Profit Margin (Annual)-26957.14%
Month-to-Date Return7.77%
Cash Flow / Share (TTM)$-1.44
EBITD / Share (Annual)$-10.81
Operating Margin (Annual)-24028.57%
LT Debt / Equity (Annual)0.74x
ROI (5Y Avg)-34.46%
LT Debt / Equity (Quarterly)0.74x
EPS Basic Excl Extra (TTM)$-10.78
P/TBV (Quarterly)0.22x
P/B Ratio (Annual)0.66x
Book Value / Share (Annual)$16.79
Price vs S&P 500 (13W)20.64%
Beta2.01x
Revenue / Share (TTM)$0.00
ROE (TTM)-55.88%
52-Week Low$5.67
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
3.88
3.88
4.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TILInstil Bio, Inc. Common Stock | — | — | — | — | $8.39 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Instil Bio is a clinical-stage biopharmaceutical company developing cell therapy treatments for cancer using tumor infiltrating lymphocytes (TILs). The company's proprietary CoStAR platform enables genetic engineering of TILs to enhance their recognition of tumor-associated antigens. Its lead candidate, ITIL-306, is in clinical development for multiple solid tumors including ovarian, uterine, non-small cell lung cancer, and renal cancer.